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Objectives 
1. Identify the most common chemotherapy-induced side 
effects and associated signs and symptoms. 
2. Identify commonly dispensed oral chemotherapy 
agents associated with chemotherapy-induced side 
effects. 
3. State possible pharmacologic treatments for the most 
common chemotherapy-induced side effects. 
4. Recognize non-pharmacologic ways in which commu-
nity pharmacists can help manage chemotherapy-
induced side effects. 
5. Identify resources available to community pharmacists 
to help manage chemotherapy-induced side effects. 
6. Recognize common limitations prohibiting community 
pharmacists from being able to manage chemotherapy 
-induced side effects. 
Abstract 
The severe side effects of chemotherapy negatively affect quality 
of life and may limit the amount of life-saving drug delivered to 
patients with cancer. These adverse events can be difficult to 
manage and evidence-based guidelines are lacking. Insufficient 
supportive care can amplify common side effects, such as 
chemotherapy-induced nausea and vomiting (CINV), myelosup-
pression, alopecia, gastrointestinal effects and neuropathy. 
Therefore, it is important to recognize the most commonly dis-
pensed chemotherapy agents and the side effects that accompany 
them. Community pharmacists, as easily accessible health care 
professionals, can provide valuable supportive care to help man-
age potentially debilitating side effects. However, a major limita-
tion when managing side effects secondary to chemotherapy is 
the limited access to patient information in most community 
pharmacies. By allowing community pharmacists increased ac-
cess to patient health records using technology, limitations ex-
perienced in practice can be averted and quality care provided. 
Introduction 
Hardships endured by cancer patients are often worsened by 
the severe side effects of chemotherapy. As health care pro-
fessionals who are easily accessible to patients, community 
pharmacists can provide valuable supportive care to help 
manage potentially debilitating side effects in individuals 
undergoing chemotherapy. This is especially true when 
dispensing oral agents that do not require administration 
within an outpatient clinic. While the chemotherapy 
regimens are often determined by strict evidence-based 
guidelines, the supportive care offered to patients is not as 
well-controlled.1 Insufficient supportive care can amplify the 
side effects of chemotherapy endured by patients such as 
chemotherapy-induced nausea and vomiting (CINV), 
myelosuppression, alopecia, gastrointestinal effects and 
neuropathy. A major obstacle to pharmacist involvement in 
managing side effects secondary to chemotherapy is the lack 
of access to patient information in most community pharma-
cies. By increasing pharmacists' access to patient health 
records using technology, limitations experienced in practice 
can be minimized to improve the community pharmacist's 
ability to provide quality care. 
Most Common Oral Chemotherapy Side Effects 
Debilitating as the disease itself may be, the difficulties faced 
by patients with cancer are often compounded by the harsh 
side effects of CINV, diarrhea, constipation, neutropenia, ane-
mia and neuropathy. Despite advances in antiemetic agents, 
CINV deters many cancer patients from completing other-
wise beneficial treatment regimens, and thus remains a para-
mount concern when antineoplastic treatment is initiated. In 
addition to causing withdrawal from treatment, nausea and 
vomiting can have detrimental effects such as serious meta-
bolic disorders, nutritional depletion and anorexia, deterio-
ration of patients' physical and mental status, esophageal 
tears, fractures and wound dehiscence.z CINV has variable 
onset, ranging from anticipatory (prior to chemotherapy ad-
ministration), acute (within 24 hours of initial chemotherapy 
administration) or delayed (occurring 24 hours to days fol-
lowing treatment).3 Methotrexate (Rhematrex®), temo-
zolomide (Temodar®) and capecitabine (Xeloda®) are com-
monly dispensed oral chemotherapy agents associated with 
CINV. Figure 1 outlines an algorithm for the treatment of CINV 
in an acute care setting. Options for the non-pharmacological 
management of CINV, as seen in Table 1, include wearing 
loose-fitting clothing and eating small, frequent meals. Pa-
tients may consider eating toast, crackers, and yogurt; eating 
ice cubes before meals may also reduce symptoms of CINV. 
Patients should also drink water throughout chemotherapy 
to prevent dehydration. Simple hygiene in keeping the oral 
cavity clean can also help in the management of CINV. Eating 
before a session of chemotherapy and lying flat after meals 
are not recommended. 
Antiemetic agents are commonly prescribed to help treat 
CJNV pharmacologically.4 Table 2 lists several chemotherapy 
agents at various risk categories for CINV and further offers 
40 THE PHARMACY AND WELLNESS REVIEW July 2012 Volume 3, Issue 2 
Impact of Community Pharmacists on Management of Cancer Chemotherapy and the Resulting Side Effects Oncology 
Figure 1. Flowchart of CINV Management.19 
.Ask cane-er patient with chemo-therapy 
whether h-e/she has high-risk factor of CINV 
1. Educat-e patientand car~iversaboutnon­
p harmacologic i nterventioos regarding ONV 
before chemotherapy. 
2. Ask cane-er p:atientwith chemotherapy 
wheth-er he/she has Cl NV. 
• Ask patient to rate Cl N:V using c:om mon 
terminal-ogy criteria for adwrse events 
(CTC.~E~. 
• Inform doctor if Cl NV grade is 1 to 4 
• In itiat-e continuous Cl NV assessmi! nt if 
CTCAE.is~ 1 
NO 
P rovicle non-p harmac:ologkal i nm l"lf'e ntiCJ.ns 
• Discuss Cl NV manage me ntwith patient 
and caregivers 
an antiemetic schedule for consideration. Current ClNV rec-
ommendations include a combination of a neurokinin 1 
(NK1) receptor antagonist, a 5-HT3 receptor antagonist and 
dexamethasone, depending on the emetic risk (mild, moder-
ate or severe) of the chemotherapeutic agents However, 
breakthrough CINV can occur and it is necessary for clini-
cians to monitor a patient's response to antiemetic agents 
throughout chemotherapy to maintain optimal treatment. 
Non-pharmacologic treatments such as dietary alterations or 
acupuncture have also been explored. 
Diarrhea is consistently poorly monitored and underre-
ported despite being one of the most prevalent side effects of 
chemotherapeutic agents, especially those regimens contain-
ing Adrucil® (5-fluorouracil or 5-FU) and irinotecan 
(Camptosar®). Complications can range from suboptimal 
[}a.cu me nt in ,e lettronic medical r,E!l:ord (EMR) 
Table 1: Non-pharmacological Management of CINV19 
• Wear loose fitting clothing 
• Eat small, frequent meals 
• Avoid sweet, fatty, high-salt, or spicy foods 
• Eat toast, crackers, and yogurt; drink lemon, 
grapefruit, and ginger teas 
• Eat ice cubes before meals and chemotherapy sessions 
• Do not lie flat after meals 
• Keep the oral cavity clean 
• Take deep breaths through the mouth, and place cold 
towels on head and neck 
• Discuss uncontrolled symptoms with health care 
professionals 
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therapy to fatality. Prior to treatment, clinicians may evalu-
ate risk factors for diarrhea, including age, gender, bowel 
pathology, and chemotherapy schedule. Should the patient 
experience chemotherapy-induced diarrhea, assessment of 
possible contributing factors such as diet, infection, disease 
states implicated in malabsorption or inflammation and con-
founding medications is necessary. Because of the variation 
in onset, it is recommended that patients at risk or who have 
developed treatment-induced diarrhea are monitored 
throughout therapy. Intervention consists of both pharma-
cologic and non-pharmacologic measures, depending on the 
severity and duration of the diarrhea. Some oral agents 
known to cause diarrhea include lapatinib (Tykerb®), er-
lotinib (Tarceva®) and sorafenib (Nexavar®). 6, 7.e The Na-
tional Cancer Institute (NCI) classifies the stages of diarrhea 
as shown in Table 3.6 Table 4 offers appropriate options for 
the management of each of these stages according to the 
American Society of Clinical Oncology (ASCO). First-line 
treatment of uncomplicated diarrhea consists of loperamide 
at a standard dose (initially 4 mg, then 2 mg every four hours 
or after every unformed stool; maximum of 16 mg per day) 
or an increased dose for persistent symptoms if physician 
recommended. The drug octreotide is indicated in lopera-
mide refractory diarrhea and as a preliminary treatment in 
complicated diarrhea. Fluoroquinolone antibiotics or vanco-
mycin are recommended for prophylaxis or if infectious diar-
rhea is suspected. Other treatments such as atropine, 
budesonide, diphenoxylate, activated charcoal or probiotics 
are less commonly used.9 
Like diarrhea, constipation is also a common side effect of 
numerous chemotherapy treatments that is underreported 
and undertreated. Patients undergoing chemotherapy may 
suffer from constipation due to a number of reasons includ-
ing dehydration, neuropathy, decreased exercise tolerance, 
electrolyte imbalances, antiemetic agents and use of analge-
Table 2: Emesis Risk of Various Chemotherapy Agents and Proposed CINV Treatment4 
Emetic Risk Chemotherapeutic drug Antiemetic schedule 
Cisplatin, Mechlorethamine, Streptozo- S-HT3 serotonin receptor antagonist: 
High (>90%) cin, Dacarbazine, Carmustine, Dactino- Day 1 
mycin, Cyclophosphamide (>1500 mg/ Dexamethasone: Days 1-4 
mZ) Aprepitant: Days 1-3 
Oxaliplatin, Cytarabine (> 1000 mg/ 5-HT3 serotonin receptor antagonist: 
m2), Carboplatin, lfosfamide, Cyclo-
Moderate (30 to 90%) phosphamide ( <1500 mg/m2), Doxoru- Dayl Dexamethasone: Day 1(2,3)a bicin, Daunorubicin, Epirubicin, ldaru- (Aprepitant: Days 1,2,3) bicin, ldarubicin, Irinotecan 
Paclitaxel, Docetaxel, Mitoxantrone, 
Topotecan, Etoposide, Pemetrexed, 
Low (10 to 30%) Methotrexate, Mitomycin, Gemcitabine, Dexamethasone: Day 1 Cytarabine ( <1000 mg/m2), 
Fluorouracil, Bortezomib, Cetuximab, 
Trastuzumab 
Bevacizumab, Bleomycin, Busulfan, 
Minimal ( <10%) Fludarabine, Vincristine, Vinorelbine, Prescribe as needed Vinblastine, 2-Chlorodeoxyadenosine, 
Rituximab 
•May omit days 2 and 3 if aprepitant is given; for patients receiving a combination of anthracycline and cyclophosphamide 
Table 3: NCI Classification of Stages of Diarrhea 
Toxicity Grade Diarrhea 
1 Increase of <4 stools/day over baseline Mild increase in ostomv output compared with baseline 
Increase of 4-6 stools/day over baseline 
2 Intravenous fluids >24 hours Moderate increase in ostomy output compared with baseline 
Not interfering with daily living 
Increase of> 7 stools/ day over baseline 
Incontinence 
3 Intravenous fluids 
Severe increase in ostomy output compared with baseline 
Interfering with daily living activities 
4 Life-threatening consequences (e.g., hemodynamic collapse) 
5 Death 
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Table 4: ASCO Recommended Guidelines for the Management of Treatment-induced Diarrhea6 
Diarrhea CTC grade Management 
Stop all lactose containing products 
Uncomplicated grade 1-2 Drink 8 to 10 large glasses ofliquid/day 
Eat freQuent small meals 
Hold cytotoxic chemotherapy and consider lapatinib dose reduction 
Grade 2 Administer standard dose of loperamide (consider continuation of loperamide until diar-
rhea-free for 12 hours) 
Consider hospital admission 
Administer octreotide Grade 3 or 4 diarrhea or 
grade 1or2 with complicat- Use intravenous fluids if appropriate 
ing featuresa Use prophylactic antibiotics as needed (especially if diarrhea is persistent beyond 24 hours 
or there is fever or grade 3-4 neutropenia) 
Hold both cytotoxic chemotherapy and lapatinib 
•Grade 3 cramping, nausea/vomiting, decreased performance status from baseline; >grade 2 fever, any sepsis, grade 3 or 4 
neutropenia, grade 3 bleeding, grade 2 dehydration. 
sics. Those chemotherapeutic agents that cause constipation 
most commonly are the vinca alkaloids, platinums and hor-
monal agents.10 Table 5 indicates treatment guidelines for 
prophylaxis and care of those patients suffering from chemo-
therapy-induced constipation. 
Neutropenia is a significant side effect because toxicity re-
lated to neutropenia limits the dose of chemotherapy that 
can be tolerated. Neutropenia is defined as an absolute neu-
trophil count (ANC) of less than 500 cells/mm3 or an ANC 
that is expected to decrease to Jess than 500 cells/mm3 dur-
ing the next 48 hours of monitoring.11 The degree and dura-
tion of neutropenia predispose the chemotherapy patient to 
infection due to suppression of the production of neutron-
phils, a key component of innate immunity and a significant 
sign of infection.12 Although all chemotherapy patients are at 
risk of developing neutropenia, challenges still exist in de-
termining those populations at a greater risk, and presenta-
tion of chemotherapy-induced neutropenia may be limited to 
a fever alone. Prevention of infection is key, and antibiotic, 
antiviral or antifungal prophylactic therapy is based on pa-
tient characteristics.11 It is important for pharmacists to 
Table 5: NCCN Constipation Treatment Guidelines20 
Non-pharmacologic 
Increase fluids 
Prophylactic Increase dietary fiber 
Exercise if appropriate 
stress the increased risk of infection to patients and educate 
them on the signs and symptoms. While it is difficult to rec-
ommend pharmacologic treatment from a community phar-
macist's setting, non-pharmacologic suggestions can be 
made, including limiting exposure to infection by practicing 
good hygiene and avoiding crowded public areas. 
Anemia may originate from decreased production of red 
blood cells (RBCs), increased destruction of RBCs or blood 
loss, and is characterized by a decrease in normal hemoglo-
bin concentration or RBC count. In patients undergoing can-
cer treatment, this may result from the myelosuppressive 
nature of cytotoxic chemotherapy such as Sutent® (sunitinib), 
or from the disease itself. Patients suffering from anemia can 
experience dizziness, fatigue and shortness of breath. In ad-
dition to significantly altering quality of life, anemia may fur-
ther complicate treatment due to delays associated with 
therapy. Typically anemia is treated using erythropoiesis-
stimulating agents (ESAs), blood transfusions or iron supple-
mentation to maintain hemoglobin levels and patients should 
be directed to their physician for treatment.13 Educating pa-
tients on the signs and symptoms of anemia and quickly re-
Pharmacologic 
Stimulant laxative + stool softener 
Rule out impaction/obstruction Add and titrate bisacodyl 10-15 mg 
Constipation Treat other causes (hypercalcemia, hypo- TID with goal of 1 non-forced BM Q 1-2 
kalemia, hypothyroidism, DM, medications) days 
Consider adding other laxatives 
Reassess for cause/severity such as polyethylene glycol, sorbitol, Persistent Constipation Recheck for impaction/obstruction magnesium hydroxide, magnesium 
citrate, enema, prokinetic agent 
( metoclopramide) 
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ferring them back to their physician is the best non-
pharmacologic way to care for this side effect from a commu-
nity pharmacist's standpoint. 
Neuropathy presents as a difficult side effect of many chemo-
therapeutic agents, both in terms of diagnosis and treatment. 
Unlike anemia, which can be diagnosed based on lab values 
and symptoms, neurologists managing cancer patients must 
rely largely on the pattern of neuropathy associated with 
specific agents. Neurotoxicity is often dependent on the cu-
mulative dose of the treatment; severity of neuropathy in-
creases with the duration of treatment and progression is 
halted with termination of treatment. Loss of sensations, 
paresthesia, pain and loss of motor function all vary depend-
ing on schedule of treatment and the agent used. Common 
chemotherapeutic agents implicated in neuropathy include 
platinum compounds, vinca alkaloids and taxanes. Because 
treatment of chemotherapy-induced neuropathy is typically 
symptomatic, prevention and management of risk factors, 
such as pre-existing neuropathy upon initiation of treatment, 
is key in this patient population.14 
Oncology Resources 
When patients inquire about other side effects not addressed 
above, there are a few educational resources for further in-
formation. These include The NCCN Clinical Practice Guide-
lines in Oncology website (http:/ /www.nccn.org) which 
separates treatment guidelines by site and often includes a 
section on supportive care specific to each cancer type. Addi-
tionally, access to relevant literature and case reports in on-
cology can be found at the American Society of Clinical Oncol-
ogy website (http:/ /www.asco.org). Lastly, but perhaps most 
importantly, contacting a board certified clinical oncology 
pharmacist who deals with these drugs on a daily basis 
would most likely provide the information necessary to in-
form the patient. When used together, these resources can 
help community pharmacists not entirely familiar with che-
motherapeutic drugs provide excellent, continuous care to 
patients undergoing chemotherapy. 
Clinical Trials 
Chauvelot et al. 20101s 
Community pharmacists currently aid in the management of 
multiple chronic disease states such as heart failure. Many of 
the principle strategies and services employed in heart fail-
ure care are applicable to the management of cancer chemo-
therapy as well. Chauvelot and colleagues used two sets of 
surveys to determine the role of the pharmacist in heart fail-
ure management from the viewpoints of both patients and 
pharmacists.is Patients viewed community pharmacists as a 
medication therapy specialist, but less than 40 percent of 
survey participants felt the pharmacist should take on larger 
roles in therapy management such as disease explanation 
and medical follow-up. Pharmacists felt they were knowl-
edgeable about the disease state and could educate the heart 
failure patient in 68 percent of cases. Community pharma-
cists are ideally placed to educate patients about their dis-
ease states and improve medication adherence, in addition to 
traditional roles as drug dispensing experts. The difficulty 
arises in overcoming current perceptions about the role of 
the community pharmacist from both patients and other 
health care providers. Pharmacists must also be empowered 
to play a larger role in disease state management through 
continuing education. 
Doh/er et al. 201116 
The objective of a study by Dahler et al. was to identify re-
sponsibilities of health care professionals in the management 
of cancer chemotherapy by using focus group discussions 
consisting of clinical pharmacists with a background in can-
cer care.16 Clinical pharmacists, physicians and nurses used a 
two-round Delphi process to allocate the identified responsi-
bilities specifically to the aforementioned professionals. 
Members of the DKG, Germany's largest multiprofessional 
association in oncology, completed a survey to rate their ac-
ceptance of the proposed tasks and their allocation to vari-
ous professions. The study identified areas for pharmacist 
involvement in patient education and counseling in addition 
to the prevention of drug related problems. Results showed 
that the pharmacist's role included eight of 11 proposed 
patient education tasks focused on increasing medication 
compliance. Pharmacists were also pertinent to seven of 20 
proposed tasks in preventing medication issues, including 
screening for interactions. With up to 75 percent of cancer 
patients using oral, complementary chemotherapy treat-
ments, the role of the pharmacist is crucial. Unfortunately, 
according to additional surveys, pharmacists are not yet able 
to perform their allocated tasks. The primary issue is that 
pharmacists do not feel as though they are an integral part of 
the health care team. However, as evidenced by the alloca-
tion of tasks, physicians, nurses and pharmacists are all nec-
essary to effectively manage a patient's cancer chemotherapy 
regimen. 
Community pharmacists can practice some of the roles pro-
posed for clinical pharmacists in this study. Patient educa-
tion, improving medication adherence and screening for drug 
-drug interactions are all tasks that are performed on a regu-
lar basis in the community pharmacy. Pharmacists currently 
use these services to manage heart failure; the same strategy 
can be applied to cancer chemotherapy. 
Simons et al. 201111 
Additionally, in a study assessing intensified pharmaceutical 
care, Simons et al. conducted a prospective, multi-centered, 
observational cohort study with control group.17 The inter-
vention group in the study received intensified pharmaceuti-
cal care. Subjects were recruited from three hospitals. Fifty 
subjects were enrolled in the study and divided evenly be-
tween the control group and intervention group. The intensi-
fied pharmaceutical care included education about the drug 
capecitabine, details on the treatment regimen, risks of non-
compliance and information on other current medications all 
from a registered pharmacist. Later, subjects received a 
medication dosing schedule and information on possible ad-
verse events including preventative methods. A pharmacist 
contacted each subject in the intervention group once during 
each cycle of chemotherapy via telephone to answer ques-
tions and provide further counseling. 
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Adherence to medication therapy was monitored using a 
Micro Electronic Monitoring (MEMS™) vial that registered 
every time the subject opened the container. Limitations of 
the MEMS™ system include the inability to determine if the 
patient actually swallowed the medication and how many 
pills the patient took out of the container each time it was 
opened. The primary endpoint was daily adherence. The in-
tervention group had a mean daily adherence of 96.8 percent 
which was significantly higher than 87.2 percent mean daily 
adherence in the control group. However, overall adherence 
between the two groups was not statistically significant 
though the intervention group was higher than the control 
group (97.9 percent and 90.5 percent, respectively). None of 
the subjects in the intervention group had a daily or overall 
adherence below 80 percent. Five subjects in the control 
group (21 percent) had an overall adherence below 80 per-
cent, and six subjects (25 percent) showed daily adherence 
less than 80 percent. 
This study shows that intense, individualized pharmaceutical 
care, including patient education, has the potential to im-
prove daily adherence to medications. With many oral 
chemotherapeutic agents available today, pharmacists have 
the ability to maximize patient therapy while minimizing 
compliance-related treatment failure. 
Improvement of Pharmacists' Management of Chemo-
therapy Side Effects 
Limitations must be overcome to optimize pharmacists' man-
agement of chemotherapy side effects. Due to underuse of 
health information technology (HIT), fragmented health care 
is a common concern for all patients and can be especially 
troublesome for oncology patients.1s,19 HIT consists of a vari-
ety of ways to transmit health information electronically 
among patients, health care professionals, payers and insur-
ers. Promoting national use of electronic health records 
(EHR), personal health records (PHR) and clinical data ex-
changes would create a continuum of care for patients allow-
ing health care professionals nationwide to have access to a 
patient's entire health record when needed. When dispens-
ing medications to patients in a community setting, pharma-
cists could be sure a complete drug utilization review is con-
ducted and all aspects of a patient's chemotherapy regimen, 
including side effects and drug-drug interactions are ad-
dressed. Ensuring pharmacists who directly interact with 
patients are properly informed of patients' medical history 
creates an opportunity for increased patient education re-
garding treatment side effects and improvement in chemo-
therapy adherence. 
Conclusion 
Through increased management of supportive care, commu-
nity pharmacists can decrease patient incidence of debilitat-
ing side effects. Recognizing these side effects, recommend-
ing drug therapy and educating patients on proper manage-
ment allows for optimal anticancer therapy. While limita-
tions to patient information exist, pharmacist involvement 
not only improves patients' quality of life, it allows for the 
best chance possible to fight their disease. 
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Assessment Questions 
1. Which is NOT a common chemotherapy-induced side 
effect? 
a. Nausea 
b. Constipation 
c. Loss of sight 
d. Anemia 
2. Which is NOT a common sign or symptom of anemia? 
a. Dizziness 
b. Fatigue 
c. Shortness of breath 
d. Clubbing of fingers 
3. All of the following are typical in patients suffering from 
neuropathy associated with chemotherapy EXCEPT: 
a. Neurotoxicity is often dependent on the 
cumulative dose of the treatment 
b. Severity of neuropathy increases with the 
duration of treatment 
c. Progression of neuropathy is halted with 
termination of treatment 
d. A diagnosis of neuropathy is made using clinical 
lab values 
4. Which oral chemotherapy agent is mismatched with one 
of its common side effects? 
a. Methotrexate; CINV 
b. Erlotinib; neuropathy 
c. Lapatinib; diarrhea 
d. Sunitinib; anemia 
5. What are the antiemetic medications required for a 
patient receiving highly emetogenic chemotherapy? 
a. S-HT3 serotonin receptor antagonist, 
dexamethasone, and aprepitant 
b. S-HT3 serotonin receptor antagonist and 
dexamethasone 
c. Only non-pharmacologic treatment is warranted 
at this time 
d. S-HT3 serotonin receptor antagonist 
6. What pharmacologic intervention is appropriate for a 
patient suffering from grade 2 diarrhea? 
a. Administer octreotide 
b. Administer standard dose of loperamide 
c. Use of prophylactic antibiotics 
d. Increase of lactulose containing products 
7. What non-pharmacologic suggestions should NOT be 
made to patients suffering from CINV? 
a. Wear loose fitting clothing 
b. Eat small, frequent meals 
c. Increase intake of sweet, fatty, high-salt, or spicy 
foods 
d. Eat ice cubes before meals 
8. What non-pharmacologic suggestions should be made to 
patients taking chemotherapy agents prone to causing 
neutropenia? 
a. Explain the signs and symptoms of infection 
b. Instruct patients to practice good hygiene 
c. Instruct patients to avoid large crowded areas 
d. All of the above 
9. What resources are available to aid in patient education 
and monitoring of chemotherapy agents? 
a. NCCN Clinical Practice Guidelines in Oncology 
b. ASCO website 
c. Board certified clinical oncology pharmacist 
d. All of the above 
10. A common limitation of community pharmacists' 
management of patient side effects is: 
a. The underuse of HIT 
b. Too much patient information 
c. Limited access to patients 
d. Easy access to patient lab values 
Ohio Northern University is accredited by the 
Accreditation Council for Pharmacy Education as a 
provider of continuing pharmacy education. This 
program is eligible for credit until 05/08/15. 
To receive continuing education credit for this program, you 
must answer the above questions and fill out the evaluation 
form. Please visit www.onu.edu/pharmacy to enter the re-
quired information. Please allow two to three weeks for 
electronic distribution of your continuing education certifi-
cate, which will be sent to your valid email address in PDF 
format. 
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To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below 
including your indicated answers to the assessment questions and return to: 
Office of Continuing Education at the Raabe College of Pharmacy 
Ohio Northern University 
525 South Main Street 
Ada, Ohio 45810 
Program Title: Impact of Community Pharmacists on Management of Cancer Chemotherapy and the Resulting Side Effects 
UAN: 0048-0000-12-032-HOl-P CEUs: 0.1 
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of 
continuing education credit. Certificates will be distributed as a PDF document to a valid email address. 
Name: 
Address: 
City: State: Zip: 
Phone: E-mail: 
Pharmacy License #: State: ONU Alumni? y N 
The program objectives were clear. 1 2 3 4 5 
The program met the stated goals and objectives: 
Identify the most common chemotherapy-induced side effects and 1 2 3 4 5 
associated signs and symptoms. 
Identify commonly dispensed oral chemotherapy agents associated 1 2 3 4 5 
with chemotherapy-induced side effects. 
State possible pharmacologic treatments for the most common 1 2 3 4 5 
chemotherapy-induced side effects. 
Recognize non-pharmacologic ways in which community pharmacists 
1 2 3 4 5 
can help manage chemotherapy-induced side effects. 
Identify resources available to community pharmacists to help 1 2 3 4 5 
manage chemotherapy-induced side effects. 
Recognize common limitations prohibiting community pharmacists 1 2 3 4 5 from being able to manage chemotherapy-induced side effects. 
The program met your educational needs. 1 2 3 4 5 
Content of the program was interesting. 2 3 4 5 
Material presented was relevant to my practice. 1 2 3 4 5 
Comment/Suggestions for future programs: 
Thank you! 
Answers to Assessment Questions-Please Circle Your Answer 
1. ABCD 4. A B C D 7. A B C D 10. A B C D 
2. A B C D 5. A BC D 8. A B C D 
3. A B C D 6. A BC D 9. A B C D 
Any questions/comments regarding this continuing education program can 
be directed to Lynn Bedford, Advanced Administrative Assistant for the 
Office of Continuing Education (email : l-bedford@onu.edu, phone 419-
772-1871 ). 
Ohio Northern University is accredited by the 
Accreditation Council for Pharmacy Education as a 
provider of continuing pharmacy education. This 
program is eligible for credit until 05/08/15. 
